Immuno-Biological Laboratories Co., Ltd. (TYO:4570)

Japan flag Japan · Delayed Price · Currency is JPY
1,405.00
+13.00 (0.93%)
Mar 27, 2026, 3:30 PM JST
Market Cap13.09B +168.6%
Revenue (ttm)1.03B +8.8%
Net Income364.00M +21.7%
EPS39.08 +21.7%
Shares Out9.31M
PE Ratio35.95
Forward PEn/a
Dividend6.00 (0.43%)
Ex-Dividend DateMar 30, 2026
Volume93,400
Average Volume183,800
Open1,392.00
Previous Close1,392.00
Day's Range1,375.00 - 1,435.00
52-Week Range356.00 - 3,820.00
Beta-0.27
RSI43.82
Earnings DateMay 12, 2026

About TYO:4570

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; and support research services on Alzheimer’s disease, metabolic syndrome, and cancer, as well as customized services for production of customized antibodies and development of ELISA systems. It also provides LipoSEARCH, a customized services for profiling and analyzing of lipoprotein through gel-filtrat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1982
Employees 58
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4570
Full Company Profile

Financial Performance

In fiscal year 2025, TYO:4570's revenue was 969.00 million, an increase of 18.75% compared to the previous year's 816.00 million. Earnings were 249.00 million, an increase of 33.87%.

Financial Statements